XML 52 R42.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-based Compensation -Schedule of Stock Option Activity (Details)
$ / shares in Units, $ in Thousands
9 Months Ended
Sep. 30, 2023
USD ($)
$ / shares
shares
Sep. 30, 2022
$ / shares
Options    
Outstanding as of December 31, 2022 (in shares) | shares 3,356,937  
Sesen Bio options assumed in the Merger (in shares) | shares 765,223  
Exercised (in shares) | shares (49,770)  
Granted (in shares) | shares 2,805,152  
Forfeited (in shares) | shares (87,275)  
Expired (in shares) | shares (274,922)  
Outstanding as of September 30, 2023 (in shares) | shares 6,515,345  
Exercisable as of September 30, 2023 (in shares) | shares 3,038,911  
Vested and expected to vest at September 30, 2023 (in shares) | shares 6,515,345  
Weighted average exercise price    
Outstanding as of December 31, 2022 (in USD per share) $ 1.01  
Sesen Bio options assumed in the Merger (in USD per share) 27.94  
Exercised (in USD per share) 1.72  
Granted (in USD per share) 7.14  
Forfeited (in USD per share) 4.70  
Expired (in USD per share) 23.52  
Outstanding as of September 30, 2023 (in USD per share) 6.28  
Exercisable as of September 30, 2023 (in USD per share) 6.71  
Vested and expected to vest at September 30, 2023 (in USD per share) 6.28  
Share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value (in USD per share) $ 4.42 $ 1.46
Weighted average remaining contractual term (years)    
Outstanding as of September 30, 2023 7 years 3 months 18 days  
Exercisable as of September 30, 2023 5 years 21 days  
Vested and expected to vest at September 30, 2023 7 years 3 months 18 days  
Aggregate Intrinsic Value    
Exercised | $ $ 190  
Outstanding as of September 30, 2023 | $ 10,191  
Exercisable as of September 30, 2023 | $ 8,068  
Vested and expected to vest at September 30, 2023 | $ $ 10,191